Decatur Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Decatur Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Buy	4,365 +8	+0.2%	+$3.54K	0.74%	33
2026 Q1	$1.95M	Sell	4,357 -69	-2%	-$32.2K	0.89%	30
2025 Q4	$2.01M	Sell	4,426 -238	-5%	-$103K	0.82%	30
2025 Q3	$1.83M	Buy	4,664 +26	+0.6%	+$10.9K	0.73%	32
2025 Q2	$2.06M	Hold	4,638	–	–	0.9%	29
2025 Q1	$2.25M	Buy	4,638 +10	+0.2%	+$4.66K	1.17%	25
2024 Q4	$1.86M	Sell	4,628 -67	-1%	-$31.1K	0.85%	34
2024 Q3	$2.18M	Sell	4,695 -4,206	-47%	-$2.02M	1.01%	32
2024 Q2	$4.17M	Buy	8,901 +221	+3%	+$95.9K	2.02%	11
2024 Q1	$3.63M	Sell	8,680 -88	-1%	-$37.2K	1.97%	13
2023 Q4	$3.57M	Buy	8,768 +2,780	+46%	+$1.03M	2.14%	11
2023 Q3	$2.08M	Hold	5,988	–	–	1.5%	17
2023 Q2	$2.11M	Sell	5,988 -70	-1%	-$23.6K	1.44%	20
2023 Q1	$1.91M	Sell	6,058 -974	-14%	-$292K	1.44%	22
2022 Q4	$2.03M	Buy	+7,032	New	+$2.14M	1.46%	24
2021 Q2	–	Sell	-10,495	Closed	-$2.25M	–	68
2021 Q1	$2.25M	Sell	10,495 -9,473	-47%	-$2.08M	0.78%	52
2020 Q4	$4.72M	Sell	19,968 -425	-2%	-$97.5K	0.86%	51
2020 Q3	$5.55M	Buy	20,393 +3,865	+23%	+$1.07M	1.09%	38
2020 Q2	$4.8M	Buy	+16,528	New	+$4.48M	1.27%	30

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Decatur Capital Management's VRTX Position: Q2 2026 in Review

Decatur Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.18% in Q2 2026, buying an estimated $3.54K and bringing the position to 4,365 shares worth $2.17M. The position accounts for 0.74% of the portfolio, ranked #33.

Decatur Capital Management first reported a position in VRTX in Q2 2020 and has held it in 19 quarters since. The position peaked at $5.55M in Q3 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Decatur Capital Management held 4,365 shares of Vertex Pharmaceuticals worth $2.17M as of Q2 2026.
Decatur Capital Management bought 8 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.54K.
Vertex Pharmaceuticals made up 0.74% of Decatur Capital Management's portfolio in Q2 2026, its #33 holding.
Decatur Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
Decatur Capital Management's Vertex Pharmaceuticals position peaked at $5.55M in Q3 2020.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Decatur Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.